Biogen to Acquire RayThera for ~$1B

Shots: Biogen has entered into a definitive agreement to acquire RayThera, expanding its immunology pipeline As per the deal, Biogen will acquire RayThera for ~$1B, incl. an upfront payment & clinical and regulatory milestone payments; closing is expected in Q3’26 Following closing, Biogen will lead development, manufacturing & global commercialization of RayThera’s assets, incl. the…

ByRidhi Rastogi4 days ago

NEWS

Rallybio to Merge with Avenzo Therapeutics to Advance Next-Generation Oncology Therapies

Shots: Rallybio has entered into a definitive agreement to acquire Avenzo through a merger transaction, after which the combined company will operate under the name Avenzo Therapeutics & is expected to trade on Nasdaq under the ticker symbol "AVZO" As per the deal, Avenzo shareholders will receive newly issued Rallybio shares based on the companies’…

ByRidhi RastogiJune 2, 2026

INSIGHTS+

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026

Headlines, Trends, and the Signals Shaping the Future of Biopharma A Quarter That Reset the Biopharma Narrative The first quarter of 2026 did not simply continue the momentum of the global biopharmaceutical industry; it redefined its direction. From multi-billion-dollar acquisitions and accelerating rare disease breakthroughs to AI-powered discovery collaborations and gene therapy approvals, the industry demonstrated a clear shift toward precision innovation, strategic consolidation, and next-generation…

ByRidhi RastogiApril 1, 2026

NEWS

Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B

Shots: Metsera announced entering into an amended merger agreement with Pfizer to acquire Metsera for up to $86.25 per share, including $65.60 in cash and a contingent value right of up to $20.65 Metsera’s Board of Directors noted that the U.S. Federal Trade Commission had raised potential antitrust concerns regarding Novo Nordisk’s proposed structure After…

BySaurabh ChaubeyNovember 8, 2025

INSIGHTS+

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Amgen (Part 02)

Shots: In the year 2022, Amgen was the top dealmaker, based on the total deal value, with 6 deals at a total announced value of ~$34.5B. Amgen has disclosed 5 out of the 6 deals leaving its BigHat Biosciences deal undisclosed Amgen’s acquisition of Horizon Therapeutics for a value of ~$28.3B was the key contributor…

BySenior EditorJanuary 16, 2023

Biogen to Acquire RayThera for ~$1B

Rallybio to Merge with Avenzo Therapeutics to Advance Next-Generation Oncology Therapies

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026

Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Amgen (Part 02)

Contact US

FOLLOW US